214 related articles for article (PubMed ID: 22251179)
1. Sample size determination for alternate periods of use study designs with binary responses.
Morel JG; Neerchal NK
J Biopharm Stat; 2012; 22(2):351-67. PubMed ID: 22251179
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval.
Liu GF; Zhu GR; Cui L
Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972
[TBL] [Abstract][Full Text] [Related]
3. Sample size for testing difference between two proportions for the bilateral-sample design.
Qiu SF; Tang NS; Tang ML; Pei YB
J Biopharm Stat; 2009 Sep; 19(5):857-71. PubMed ID: 20183448
[TBL] [Abstract][Full Text] [Related]
4. Tests for inter-subject and total variabilities under crossover designs.
Lee Y; Shao J; Chow SC; Wang H
J Biopharm Stat; 2002 Nov; 12(4):503-34. PubMed ID: 12477072
[TBL] [Abstract][Full Text] [Related]
5. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
Nguyen TT; Bazzoli C; Mentré F
Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
[TBL] [Abstract][Full Text] [Related]
6. On sample size determination in multi-armed confirmatory adaptive designs.
Wassmer G
J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
[TBL] [Abstract][Full Text] [Related]
7. Sample size planning with the cost constraint for testing superiority and equivalence of two independent groups.
Guo JH; Chen HJ; Luh WM
Br J Math Stat Psychol; 2011 Nov; 64(3):439-61. PubMed ID: 20704777
[TBL] [Abstract][Full Text] [Related]
8. On the role of Baseline measurements for crossover designs under the self and mixed carryover effects model.
Liang Y; Carriere KC
Biometrics; 2010 Mar; 66(1):140-8. PubMed ID: 19432775
[TBL] [Abstract][Full Text] [Related]
9. A note on sample size calculation for mean comparisons based on noncentral t-statistics.
Chow SC; Shao J; Wang H
J Biopharm Stat; 2002 Nov; 12(4):441-56. PubMed ID: 12477068
[TBL] [Abstract][Full Text] [Related]
10. Design and analysis of crossover trials for absorbing binary endpoints.
Nason M; Follmann D
Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
[TBL] [Abstract][Full Text] [Related]
11. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
12. Crossover designs with correlated observations.
Donev AN
J Biopharm Stat; 1998 May; 8(2):249-62. PubMed ID: 9598421
[TBL] [Abstract][Full Text] [Related]
13. Cluster randomised crossover trials with binary data and unbalanced cluster sizes: application to studies of near-universal interventions in intensive care.
Forbes AB; Akram M; Pilcher D; Cooper J; Bellomo R
Clin Trials; 2015 Feb; 12(1):34-44. PubMed ID: 25475880
[TBL] [Abstract][Full Text] [Related]
14. Estimating standardized linear contrasts of means with desired precision.
Bonett DG
Psychol Methods; 2009 Mar; 14(1):1-5. PubMed ID: 19271844
[TBL] [Abstract][Full Text] [Related]
15. Optimal crossover designs for logistic regression models in pharmacodynamics.
Waterhouse TH; Eccleston JA; Duffull SB
J Biopharm Stat; 2006; 16(6):881-94. PubMed ID: 17146986
[TBL] [Abstract][Full Text] [Related]
16. Multivariate Mann-Whitney estimators for the comparison of two treatments in a three-period crossover study with randomly missing data.
Kawaguchi A; Koch GG
J Biopharm Stat; 2010 Jul; 20(4):720-44. PubMed ID: 20496202
[TBL] [Abstract][Full Text] [Related]
17. Design and analysis issues for crossover designs in phase I clinical studies.
Boon PC; Roes KC
J Biopharm Stat; 1999 Mar; 9(1):109-28. PubMed ID: 10091913
[TBL] [Abstract][Full Text] [Related]
18. Towards power and sample size calculations for the comparison of two groups of patients with item response theory models.
Hardouin JB; Amri S; Feddag ML; Sébille V
Stat Med; 2012 May; 31(11-12):1277-90. PubMed ID: 22069169
[TBL] [Abstract][Full Text] [Related]
19. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
Friede T; Kieser M
Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
[TBL] [Abstract][Full Text] [Related]
20. Group sequential and discretized sample size re-estimation designs: a comparison of flexibility.
Wu X; Cui L
Stat Med; 2012 Oct; 31(24):2844-57. PubMed ID: 22733405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
